Main Article Content
Imatinib, Hyperpigmentation, Dermal Melanocytosis, BCR-ABL Inhibitor
Background: Imatinib, a tyrosine kinase inhibitor targeting bcr-abl, c-Kit, and PDGF receptors-alpha and beta, is commonly used to treat GI stromal tumors and hematologic malignancies. Hyperpigmentation is a known side-effect of imatinib, with intradermal hemosiderosis being the most common histologic finding.
Case Presentation: We report a rare case of concurrent hypopigmentation and hyperpigmentation secondary to dermal melanocytosis following imatinib treatment in an African American patient with acute lymphoblastic leukemia.
Conclusion: Early referral to dermatology in patients with similar findings is appropriate given the increased risk of melanoma conferred by heightened melanocyte proliferation.
2. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006;5:228–231.
3. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358-9.
4. Pureesrisak P, Tienthavorn T. Imatinib mesylate induced acquired dermal melanocytosis: a rare case report. Thai Journal of Dermatology. 2017; 33(4): 297-305.
5. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-8.
6. Maiti B, Setrakian S, Daw HA. Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report. Cases J. 2009; 2:7526.
7. Kok WL, Chen Q, Lee SSJ, Chua SH, Ng SK. A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis. J Dermatolog Treat. 2017;28(8):762–3.
8. Baykal C, Yılmaz Z, Sun GP, Büyükbabani N. The spectrum of benign dermal dendritic melanocytic proliferations. J Eur Acad Dermatol Venereol. 2019;33(6):1029-1041.
9. Tse JY, Walls BE, Pomerantz H, Yoon CH, et al. Melanoma arising in a nevus of Ito: novel genetic mutations and a review of the literature on cutaneous malignant transformation of dermal melanocytosis. J Cutan Pathol. 2016;43(1):57-63.
10. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-6.
11. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-90.